## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($327.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline**
- Source: Finviz | 20260107T150907 | Bullish | Relevance: 100%
- Amgen has acquired Dark Blue Therapeutics for $840 million to enhance its oncology pipeline. This acquisition adds a preclinical small-molecule degrader targeting acute myeloid leukemia (AML), a disease for which Amgen currently has no marketed therapy. The move emphasizes Amgen's commitment to expanding its oncology presence and leveraging innovative treatments.

**2. Amgen buys Dark Blue Therapeutics in $840m oncology deal**
- Source: Pharmaceutical Technology | 20260107T121151 | Bullish | Relevance: 100%
- Amgen has acquired UK-based Dark Blue Therapeutics for up to $840m, marking the first major pharma takeover of 2026. This acquisition grants Amgen access to Dark Blueâ€™s oncology pipeline, including DBT 3757, an investigational treatment for acute myeloid leukaemia. The deal signals Amgen's renewed focus on early-stage drug development and dealmaking after a period of less activity.

**3. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52**
- Source: Simply Wall Street | 20260107T101324 | Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ:AMGN) is set to increase its dividend to $2.52, offering a 3.1% yield. The company's dividend payout is considered sustainable, with only 47% of free cash flow being used for payments and a forecast earnings per share growth of 21.3% next year. Despite limited earnings growth over the past five years, Amgen has a solid track record of consistently growing dividends at an average annual rate of 12% since 2016.

**4. Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report**
- Source: BioCentury | 20260107T001700 | Bullish | Relevance: 100%
- Amgen Inc. has acquired U.K.-based Dark Blue Therapeutics Ltd. gaining a preclinical small molecule targeting MLLT1 and MLLT3 for acute myelogenous leukemia (AML). The deal's total value could reach $840 million based on milestones, though the upfront payment was not disclosed. This acquisition marks a significant biotech M&A transaction early in 2026.

**5. UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380**
- Source: GuruFocus | 20260106T230855 | Bullish | Relevance: 100%
- UBS has upgraded Amgen (AMGN) to a "buy" rating, increasing its price target to $380 due to the promising potential of its late-stage developments, MariTide and olpasiran. Amgen, with a market capitalization of $177.79 billion, demonstrates strong financial health as indicated by a high Piotroski F-Score. Despite some insider selling and a high debt-to-equity ratio, the company maintains robust revenue growth and profitability.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 15.6x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $184.0B |
| Beta | 0.45 |
| 52W Range | $259.82 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 15.6 |
| Current P/E | 16.1 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.2% to 2.9% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 2.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.88% (CS: 79) | Neutral |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 0.43 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.146x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $341.64
- **Stop Loss:** $327.88 (4.0% risk)
- **Target:** $355.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 87
- **Position Value:** $29,722.68
- **Portfolio %:** 29.72%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*